126 results about "Urinary protein" patented technology

The invention discloses an ultrasound-based diabetic renal lesion risk detection method and system, and relates to the technical field of ultrasonic detection.According to the system, through continuous scanning of a two-dimensional ultrasonic probe, an elastic imaging probe and a Doppler probe, the shape, structure, blood flow characteristics and cortex images of the kidney are obtained; an image processing technology is adopted for preprocessing, space registration and fusion, and a kidney area is automatically segmented; according to the extracted kidney tissue characteristics, calculating an atrophy risk coefficient and a fibrosis risk coefficient, and comparing with a standard threshold value to evaluate the kidney lesion risk; calculating a comprehensive risk coefficient in combination with blood glucose, urine protein and diet data, and evaluating diet influence risks; a renal lesion risk assessment model is constructed by using a convolutional neural network and a machine learning algorithm, a renal lesion prediction function is generated, and the system can accurately assess the renal lesion risk of a diabetic patient and provide early diagnosis and personalized treatment suggestions.

The invention belongs to the technical field of microorganisms, and particularly relates to application of Ackerman muciniphila in preparation of diabetic metabolic disease related renal injury products. The preservation number of the ackermann muciniphile is CGMCC (China General Microbiological Culture Collection Center) No.20955. The ackermann muciniphile provided by the invention can be used for remarkably reducing the indexes of blood urea nitrogen, serum creatinine and urine protein and improving the renal function; the oxidative stress of the kidney is relieved by reducing the malondialdehyde level and improving the activity of SOD, CAT and GSH-Px; the TLR4 / NF-kappa B pathway is inhibited, TNF-alpha and IL-1beta secretion is reduced, and inflammatory response is relieved; finally, the kidney protection effect is achieved through the anti-oxidation, anti-inflammatory and anti-fibrosis effects.

The invention provides a diabetic nephropathy early warning method, system, equipment and medium, and relates to the technical field of medical data analysis and prediction.The method comprises the steps that multiple urine samples of a user are collected, target urine protein detection is conducted, and multiple urine protein concentrations are obtained; each urine protein concentration is combined with a normal urine protein concentration set to be input into an abnormal data recognition tree, the number of layers of multiple recognition nodes is obtained, and the detection confidence coefficient is obtained through calculation; configuring an abnormal proportion according to the detection confidence coefficient, inputting a plurality of urine protein concentration combination normal urine protein concentration sets into an abnormal data identification tree, deleting urine protein concentrations divided into abnormal data in the abnormal proportion before, and obtaining screened urine protein concentrations; according to the screened urine protein concentration, an auxiliary early warning coefficient is obtained through calculation, and early warning is carried out. The technical problem of low early warning accuracy of diabetic nephropathy in the prior art is solved.

The invention discloses a traditional Chinese medicine compound for reducing urine protein, a traditional Chinese medicine preparation and a preparation method thereof, belongs to the technical field of traditional Chinese medicine compounds, and solves the problems that although the existing western medicine can reduce the urine protein level of a patient to a certain extent, the adverse reaction risk is high; the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-30 parts of prepared rehmannia root, 10-30 parts of Chinese yam, 10-30 parts of dogwood, 10-20 parts of achyranthes root, 5-15 parts of schisandra chinensis, 5-15 parts of semen cuscutae, 10-30 parts of corn stigma, 10-30 parts of rhizoma alismatis, 10-30 parts of astragalus membranaceus, 10-30 parts of fried fructus rosae laevigatae, 10-30 parts of gordon euryale seed, 5-15 parts of flatstem milkvetch seed, 5-30 parts of salvia miltiorrhiza, 3-10 parts of wine-treated rhubarb and 3-5 parts of wine-treated coptis chinensis. According to the traditional Chinese medicine composition, all the medicines are compatible, all the components complement each other, the effects of reducing urinary albumin and protecting the kidney are increased, all the components are reasonably compatible, and the effect of coordinating and synergism is achieved.

The invention belongs to the technical field of molecular biology, and particularly relates to a construction method and application of a streptococcus pneumoniae pneumonia animal model. The invention provides a construction method of a streptococcus pneumoniae infected rat pneumonia and kidney injury model. The method comprises the following steps: S1, applying a streptococcus pneumoniae liquid into the respiratory tract of a rat by adopting an atomization bacterium feeding mode; and S2, verifying whether the rat treated in the step S1 is infected with pneumonia or not and whether kidney injury exists or not. According to the method, whether pneumonia is infected or not is judged by detecting inflammatory factors in alveolar lavage and lung HE staining, and whether kidney injury exists or not is judged by detecting the urine protein / creatinine ratio in a rat urine sample and detecting kidney HE staining. The construction method provided by the invention is convenient to operate, accurate in model construction and high in survival rate.

The invention discloses a novel compound and application thereof in preparation of a medicine for treating systemic lupus erythematosus. In-vitro experiments show that the compound provided by the invention can further inhibit the secretion of anti-dsDNA IgG + B cell subtype mediated autoantibody by inhibiting the process that B cells are differentiated into plasmoblasts; in-vivo experiments show that the compound provided by the invention can effectively reduce the content of total IgG and anti-dsDNA-IgG in peripheral blood of a systemic lupus erythematosus model mouse, inhibit splenomegaly and peripheral lymph node hyperplasia of the mouse, slow down urine protein increment of the mouse, inhibit glomerular lesion and renal tubule lesion of the mouse and inhibit IFN-gamma generation of the mouse kidney; differentiation of spleen and peripheral lymph node plasmablasts of mice is inhibited, that is, differentiation and function development (antibody secretion) processes of B cells are directly acted. Therefore, the compound provided by the invention has a prospect of being developed into drugs for treating systemic lupus erythematosus.

The invention provides a traditional Chinese medicine composition for treating nephropathy as well as a preparation method and application thereof, and the anti-renal fibrosis effect is remarkably improved by optimizing a leech extraction process and a novel preparation technology. Animal experiments show that urine protein of model animals can be reduced by 67% and serum creatinine can be reduced by 42% after 12 weeks of continuous administration. Clinical tests prove that the traditional Chinese medicine composition has a definite curative effect on IgA nephropathy, membranous nephropathy and the like, and a new choice is provided for treating chronic kidney diseases.

The application belongs to the field of medicine, and particularly relates to application of a Danzhu Fuguan formula in preparation of a drug for treating idiopathic membranous nephropathy (IMN). The Danzhu Fuguan formula comprises the following raw materials in parts by weight: 25-35 parts of Danshen, 10-15 parts of Baizhu, 25-35 parts of Huangqi, 10-20 parts of Jinyinhua, 10-20 parts of Hujiang, 10-20 parts of Yujin, 10-15 parts of Fuling, 25-35 parts of Yiyiren and 10-15 parts of Qianghuo. Research shows that the Danzhu Fuguan formula can effectively reduce the 24-hour urine protein level of IMN patients, and the 24-hour urine protein level shows a significant downward trend with the extension of the treatment course; according to the IMN clinical efficacy standard, the total remission rate of patients receiving the Danzhu Fuguan formula treatment for 3 months is 37%, the total remission rate of patients receiving the treatment for 6 months is 50%, and the total remission rate of patients receiving the treatment for 12 months reaches 72%, and the remission rate increases significantly with the extension of the treatment course.

The utility model discloses an integrated 24-hour quantitative urine protein collecting container which is characterized by comprising a container body and a container cover, the container body is used for storing a urine sample, and the container cover is used for covering and sealing the container body; a telescopic strip-shaped body extends from one side, facing the interior of the container main body, of the container cover, a sampling structure is arranged at one end, facing the interior of the container main body, of the strip-shaped body, a handle part is arranged on one side, facing the exterior, of the container cover, a cavity is formed in the handle part, an elastic device is arranged in the cavity, and the elastic device is arranged in the cavity. One end of the elastic device is fixed to the inner side of the handle part, and the other side of the elastic device is fixed to the end, facing the container cover, of the strip-shaped body.

The invention relates to a urine protein marker for depression and bipolar affective disorder and application of the urine protein marker in early diagnosis. Specifically, the invention relates to application of a reagent for detecting the content of protein in urine of a subject in preparation of a reagent for diagnosing depression and bipolar affective disorder, and the protein in the urine is selected from the following combinations: Uniprot ID: P11766, H7BY57, O95967, O95433, K7ELM9, P15328 and P68371.

The invention provides a portable stable urine protein qualitative detection kit, and relates to the technical field of urine protein qualitative detection. A homogenizing tank is fixedly mounted at the front end in the kit body, a conveying pipe is connected to the middle in the homogenizing tank in a penetrating manner, through holes in an annular array are formed in the surface of the position, located in the homogenizing tank, of the conveying pipe, and a limiting sleeve is fixedly connected to the top of the conveying pipe. A uniform tank is arranged in the kit, a bevel gear and an annular gear are driven by a motor, and a vertical plate at the bottom of the annular gear is driven to rotate in the uniform tank, so that a liquid sample can be fully and uniformly stirred, protein in the sample can be more uniformly distributed, and a detection result can more accurately reflect the actual content of protein in urine; and the detection reliability is improved. The problems that a kit is lack of an effective sample uniform treatment mechanism, if a urine sample is not fully uniform before detection, the protein concentration of a detection part is inconsistent, and the detection result has deviation are solved.

The invention belongs to the technical field of biological medicines, and particularly relates to application and a method of PHF20 in preparation of a medicine for treating systemic lupus erythematosus and the medicine. The invention discloses an application of PHF20 in treatment of systemic lupus erythematosus, a lentivirus with murine PHF20 is selected as a gene therapy tool, an R848 induced lupus mouse model is taken as an experimental subject for gene therapy, and results show that injection of the overexpressed PHF20 lentivirus in a lupus mouse body has the following effects: (1) spleen swelling is improved, and spleen index is significantly reduced; (2) reducing urine protein, urea nitrogen level, anti-dsDNA antibody level and IgG antibody level of the model mouse; and (3) the pathological damage to the kidney of the model mouse is relieved. The research results show that the PHF20 serving as the target provides important reference value for potential application prospects in systemic lupus erythematosus gene therapy and even autoimmune disease gene therapy.

1. The name of the design product: storage (urine protein). 2. The use of the design product: for urine protein detection sample storage. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

The invention belongs to the technical field of biology, and particularly relates to a group of urine protein markers and application thereof in preparation of non-small cell lung cancer prognosis prediction products. A group of urine proteins including AVIL protein, CXCR5 protein, ENPEP protein, DPEP1 protein, SNC66 protein and XPNPEP2 protein which are closely related to non-small cell lung cancer postoperative progress are screened out from urine of non-small cell lung cancer patients for the first time; a prognosis prediction model is constructed based on the six kinds of urine proteins, the constructed prognosis prediction model is verified to have high sensitivity and specificity on prognosis prediction of non-small cell lung cancer postoperative patients, the sensitivity and the specificity respectively reach 84.5% and 81.2%, and the prognosis prediction model has a good prognosis prediction effect on non-small cell lung cancer. Reliable guidance is provided for clinical targeted treatment, and important significance is achieved for improving prognosis survival conditions of non-small cell lung cancer patients.

An exemplary embodiment includes obtaining, by a computing system, observed values of an individual's demographic values, an individual's vital sign values, and an individual's blood test values; applying, by the computing system, a machine learning model to the observed values; providing, by the computing system, a prediction as to whether the individual exhibits undiagnosed albuminuria or proteinuria based on the observed values; and the machine learning model is trained by a training dataset. The training dataset includes corresponding demographic values, vital sign values, blood test values, and observed values of either a urine albumin-to-creatinine ratio (UACR) value or a urine protein-to-creatinine ratio (UPR) value for a plurality of individuals. The machine learning model is configured to provide a prediction as to whether further observed values indicate undiagnosed albuminuria or proteinuria.

Provided is a pharmaceutical composition and use thereof in treating a chronic kidney disease. In the pharmaceutical composition, Astragalus membranaceus is adopted for strengthening body resistance, and Radix et Rhizoma Rhei, Whitmania pigra (W. pigra), and Bombyx batryticatus (B. batryticatus) are adopted for eliminating pathogens, that is, the pharmaceutical composition can improve a kidney function through the combination of strengthening body resistance with eliminating pathogens. The above treatments all can significantly reduce creatinine, urea nitrogen, and urine protein / creatinine ratio indexes in rats with chronic renal failure (CRF), and improve pathological changes such as glomerular mesangial expansion, extracellular matrix deposition of mesangial cells, glomerulosclerosis, and renal interstitial fibrosis (RIF) in rats (a model) with CRF, thereby further improving a therapeutic effect of the TCM composition for CKD.

This invention provides a physiological age prediction model that predicts the physiological age of a subject by detecting urinary proteins and metabolites in a urine sample. The aforementioned urinary proteins and metabolites are those that change significantly with age, including one or more selected from the following: cartilage intermediate layer protein (CILP2), collagen Alpha 1 chain (COFA1), myristic acid, 12-methyltridecanoic acid, CN family member 5 (CCN5), Sushi domain-containing protein 5 (SUSD5), procollagen C endopeptidase enhancer 1 (PCOLCE), and L-lactate oxidase (LOX), preferably including all of the aforementioned urinary proteins and metabolites.

The invention belongs to the field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition and a preparation and application thereof. A compatibility system of monarch, minister, assistant and guide is adopted, rhizoma atractylodis, semen coicis and cortex phellodendri are taken as monarch drugs, polygonum cuspidatum, centella asiatica and fructus kochiae are taken as minister drugs, prepared rheum officinale, radix achyranthis bidentatae and caulis spatholobi are taken as guide drugs, gynostemma pentaphyllum, radix paeoniae alba and rhizoma polygonati are taken as adjuvant drugs, the medicinal materials are compounded according to a specific mass ratio, and the mass ratio of the monarch drugs to the minister drugs to the adjuvant drugs to the guide drugs is (50-80): (50-80): (30-55): (35-70). The traditional Chinese medicine composition provided by the invention can remarkably reduce the levels of blood uric acid, serum creatinine and urea nitrogen, reduce urine protein excretion and improve inflammation, a hypercoagulation state and lipid metabolism disorder, the total effective rate reaches 90%, the adverse reaction is slight, and the recurrence rate is low.

The invention discloses an amniotic epithelial cell-derived exosome for treating gestational hypertension and application thereof, and belongs to the technical field of biological medicines. The exosome (hAECs-exos) is obtained by secreting and extracting human amniotic epithelial cells (hAECs), the particle size distribution of the exosome (hAECs-exos) is 30-150 nm, and the exosome (hAECs-exos) expresses exosome specific markers CD9, CD63 and CD81. The invention also provides a preparation method of the exosome. The preparation method comprises the following steps: isolated culture of hAECs, and ultracentrifugal extraction and identification of the exosome. Animal experiments prove that when the exosome is applied to a gestational hypertension disease model animal in an intravenous injection mode, the blood pressure and urine protein level of the gestational hypertension disease model animal can be remarkably reduced, and the fetal rat dysplasia condition is improved. The invention provides a brand-new and effective biological preparation candidate scheme for the treatment of the gestational hypertension disease.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a kidney-tonifying, mass-eliminating and wind-dispelling prescription for preventing and treating diabetic nephropathy as well as a preparation method and application thereof. The kidney-tonifying, mass-eliminating and wind-dispelling prescription consists of astragalus membranaceus, pseudo-ginseng, caulis spatholobi, honeysuckle stem, rhizoma sparganii, common yam rhizome and gordon euryale seed, the seven medicines supplement one another, and the treatment thought of tonifying qi, nourishing blood, dispelling wind, dredging collaterals, eliminating mass and reinforcing kidney is combined on the basis that'deficiency stasis with rheumatism 'is taken as the core pathogenesis of diabetic nephropathy. The traditional Chinese medicine composition is designed aiming at the common clinical manifestations of diabetic nephropathy, such as urine protein rise, limb numbness, edema and renal hypofunction, plays a role in comprehensive regulation and layered intervention, embodies the innovative concept of combining traditional Chinese medicine syndrome differentiation treatment and modern disease spectrum, and has relatively high industrial value.

The application discloses a liposome curcumin composition for assisting in controlling blood sugar and regulating kidney and application thereof, and belongs to the technical field of food and health food. The composition adopts a modular formula design and comprises a basic active component and an optional kidney protection component. The particle size of the liposome curcumin is accurately controlled to be 60-80 nm, the encapsulation rate is greater than or equal to 80%, the ethanol residue is less than or equal to 0.5 ‰, the gastric juice 2h release rate is less than 33%, and the intestinal juice 2h release rate is greater than 80%. By differentially adjusting the component amount, two scenes of simple blood sugar reduction and blood sugar reduction and kidney protection can be adapted, and bidirectional synergy of stable blood sugar regulation and kidney target maintenance can be realized. The application also provides application of the composition in oral liquid, solid beverage, soft capsule and tablet. It is verified through experiments that the bioavailability of the composition is more than 12 times higher than that of conventional curcumin preparation, the postprandial blood sugar peak value is reduced by 25%-30%, the urinary protein excretion rate is reduced by 18%-22%, the safety and compliance are excellent, and the composition is suitable for industrial production.

The present invention relates to a pharmaceutical composition for treating chronic glomerulonephritis, its preparation method and application. The pharmaceutical composition is composed of Rhizoma Smilacis Glabrae Albae, Flos Abelmoschi Manihot, Herba Ephedrae Delavayi, Radix Saposhnikoviae Divaricatae, Ramulus Ulmi Pumilae, Herba Dichondrae Repentis, Rhizoma Corydalis Saxicolae, Radix Salviae Yunnanensis, and Radix Achyranthis Aspera. The preparation method is to first extract the above nine herbs with ethanol and then with water, and the mixed solution is concentrated to make a pharmaceutical preparation. The combined use of this pharmaceutical preparation and western medicine can improve the treatment effect of chronic glomerulonephritis, with a total effective rate reaching 84%. Moreover, it can significantly reduce the urinary protein and red blood cells in patients, showing a significant difference compared with the control group using western medicine alone. This indicates that it can effectively improve the clinical symptoms of patients, has no adverse reactions, has high safety, and has extremely high popularization value.

The invention discloses a pentapeptide YP5 with a function of relieving diabetic kidney injury as well as a preparation method and application of the pentapeptide YP5, and belongs to the technical field of biology. The pentapeptide YP5 is screened from pacific salmon protamine enzymatic hydrolysate, the amino acid sequence is YVAAP, and the pentapeptide YP5 has the function of relieving the diabetic kidney injury, can remarkably reduce the content of fasting blood-glucose, serum creatinine, urea nitrogen and urine protein of diabetic mice, has better activity and smaller toxic and side effects than a positive drug metformin, and can be used for preparing the medicine for treating diabetic kidney injury. The method can be applied to functional food for relieving diabetic kidney injury.

The present invention relates to a traditional Chinese medicine composition for treating diabetic nephropathy and a preparation method thereof, belonging to the technical field of traditional Chinese medicine compositions. To solve the problems of single target for western medicine in treating diabetic nephropathy and high risk of adverse reactions when using a combination of multiple drugs, the present invention provides a traditional Chinese medicine composition for treating diabetic nephropathy. The composition formula includes white ginseng, astragalus membranaceus, stir-fried atractylodes macrocephala, poria cocos, chicken gizzard-membrane, kudzu root, wolfberry fruit, Chinese yam, cornel fruit and oriental waterplantain rhizome. The traditional Chinese medicine composition of the present invention has the advantages of multiple components and multiple targets and small adverse reactions. Animal experiments prove that the traditional Chinese medicine composition provided by the present invention can significantly improve the blood glucose, blood lipid, urine protein, creatinine and blood urea nitrogen levels of rats, can significantly improve the pathological changes of the renal tissue of model rats, and can correct the podocyte metabolic pathway and restore its mitochondrial function by specifically increasing the activities of SIRT1 and PGC-1α. It is an effective medicine for treating diabetic nephropathy and provides a new way for the multi-target treatment of clinical diabetic nephropathy.

The present invention provides the use of GppNHp in the preparation of a medicament for treating systemic lupus erythematosus, belonging to the technical field of medicine. By using the necroptosis inhibitor GppNHp, the present invention can significantly alleviate various symptoms of lupus model mice, such as significantly reducing the volume and weight of the spleen and lymph nodes, slowing down kidney injury, reducing urinary protein, decreasing the concentration of tumor necrosis factor (TNF-α), and increasing the concentration of complement C3. The preparation provided by the present invention can effectively improve the symptoms of lupus mice and is expected to improve the quality of life of SLE patients.

The invention discloses a folium cortex eucommiae extract and application of the folium cortex eucommiae extract in prevention and treatment of adriamycin nephropathy, and relates to the technical field of medicines, the folium cortex eucommiae extract is prepared from dried folium cortex eucommiae through water extraction, heating at 65 DEG C, ultrasonic assistance and vacuum freeze drying, LC-MS / MS analysis shows that the folium cortex eucommiae extract contains no less than 200 components, the components mainly comprise flavonoids, terpenes and phenylpropanoids, and the content of the flavonoids, the terpenes and the phenylpropanoids is no less than 100%. The folium cortex eucommiae extract has no obvious cytotoxicity to HK-2 and HBZY-1 cells under the concentration of 0-1500mu g / mL, can be used for preparing medicines for preventing and treating adriamycin nephropathy, inhibits kidney cell apoptosis by down-regulating Bax and up-regulating Bcl-2 and obviously reduces the levels of IL-6, IL-1beta and TNF-alpha in serum, and in an animal model, 150-600mg / kg of the folium cortex eucommiae extract is continuously administrated for 21-30 days in an intragastric manner, so that the effect of preventing and treating adriamycin nephropathy is achieved. The traditional Chinese medicine composition can effectively relieve weight loss, reduce urine protein, serum creatinine and urea nitrogen, increase albumin and improve kidney pathological injury, and is suitable for relieving kidney toxicity in a prophylactic or therapeutic mode in subjects receiving adriamycin chemotherapy.

The invention relates to a method for constructing a preeclampsia prediction model by using clinical laboratory data and a related application thereof. Specifically, the preeclampsia risk prediction model is constructed based on a plurality of clinical indexes of pregnant women, a plurality of clinical laboratory data and insulin growth binding factor binding protein 1 and / or placental growth factors. The clinical laboratory data comprises leukocyte count and / or urine protein, and further comprises any one or combination of platelet count, monocyte proportion, glutamic-straw / glutamic-pyruvic transaminase ratio, glutamyltranspeptidase, uric acid and high-density lipoprotein. The constructed preeclampsia risk prediction model can provide a reliable implementation means for early prevention and early treatment of preeclampsia. Meanwhile, the sensitivity of the prediction model is 88.0% when the specificity of early eclampsia is 85.04% and the sensitivity of the prediction model is 62.5% when the specificity of late eclampsia is 85.04% in a complete independent verification set, and the detection performance of the prediction model is higher than that of the current detection performance.

This invention relates to the field of biomedical technology, and particularly to the application of crotonin A in the preparation of drugs for treating IgA nephropathy. Pharmacodynamic experiments conducted in vivo on a Thy1 rat model showed that crotonin A effectively reduced 24-hour urinary protein and the urinary protein-to-creatinine ratio in an IgA nephropathy model—an anti-Thy1 rat nephritis model—and inhibited the expression of mRNAs of genes related to renal cortical inflammation, proliferation, and fibrosis, including Cyclin E, α-SMA, FN, CCL2, NF-κB, and IL-6, further improving renal pathology. In in vitro cell models, crotonin A inhibited the proliferation of rat mesangial cells and suppressed the expression of mRNAs of TGF-β, Cyclin E, α-SMA, CCL2, NF-κB, and IL-6, indicating that crotonin A has significant anti-inflammatory, anti-cell proliferation, and anti-fibrotic effects. Brucella oleracea has considerable therapeutic potential, providing a potential new drug option for the clinical prevention and treatment of IgA nephropathy, and is of great significance for the development of safe and effective drugs for the treatment of IgA nephropathy.

This invention discloses the application of SNCG protein in the auxiliary diagnosis of prostate cancer, belonging to the field of biomedical technology. The application involves using reagents specifically designed to detect SNCG protein expression in biological samples to prepare products for the auxiliary diagnosis of prostate cancer. Through proteomic analysis of urinary proteins from prostate cancer patients and normal men, this invention revealed that the concentration of SNCG protein in the urine of prostate cancer patients was significantly higher than that in the normal male group. Immunohistochemical analysis of paraffin-embedded tissue samples from prostate cancer patients and surrounding normal prostate tissue showed that SNCG protein has a certain expression rate in prostate cancer, and that SNCG protein is also expressed in the basal cells of normal prostate glands, indicating a certain relationship between SNCG protein and the occurrence and development of prostate cancer. This invention can be used to assist in the diagnosis of prostate cancer and difficult cases, thereby improving the diagnosis rate and survival rate of patients.

This invention provides a method and storage medium for detecting the pathological type of pulmonary nodules, belonging to the field of medical technology. The method for detecting the pathological type of pulmonary nodules includes: acquiring urinary protein expression profile data of pulmonary nodules from an individual sample to be analyzed; preprocessing the urinary protein expression profile data to obtain standardized data based on a summation of quantitative data; inputting the standardized data into a pre-constructed classifier; and the pre-constructed classifier performing feature matching and prediction on the input data to output the pathological type classification result of the individual sample to be analyzed. This invention addresses the problems of physical harm and psychological burden on patients, as well as inconsistent diagnostic results, caused by traditional methods for detecting the pathological type of pulmonary nodules.